TABLE 2.
Summary of clinical data for patients examined by using the ICS technique
| Parameter | Value for group
|
|
|---|---|---|
| HBV monoinfected, on therapy | HIV-HBV coinfected on therapy | |
| No. of patients | 13 | 14 |
| No. positive/total (% positive) | ||
| HBsAg | 13/13 (100) | 14/14 (100) |
| Current HBeAg | 2/6 (33.3) | 7/12 (58.3) |
| Ever HBeAg | 5/13 (38.5) | 10/13 (76.9) |
| Current HBeAb | 3/6 (50.0) | 3/12 (25.0) |
| Ever HBeAb | 9/13 (69.2) | 4/13 (30.8) |
| Precore mutanta | 7/8 (87.5) | 1/5 (20.0) |
| HBV viral load (copies/ml) | ||
| Mean ± SD | 5.82 × 107 ± 1.48 × 108 | 4.10 × 105 ± 9.11 × 105 |
| Range | 2,000-4.66 × 108 | 2,000-2.69 × 106 |
| No. with undetectable viral load/total (% with undetectable viral load) | 6/10 (60.0) | 9/12 (75.0) |
| ALT (U/liter) | ||
| Mean ± SD | 43.5 ± 38.3 | 53.5 ± 35.9 |
| Range | 14-132 | 14-136 |
| Current or recent therapy duration (mo) | ||
| Mean ± SD | 20.2 ± 15.6 | 22.1 ± 22.6 |
| Range | 2-46.5 | 1-60 |
| No. receiving treatment/total (% receiving treatment) | ||
| Lamivudine | 10/13 (76.9) | 14/14 (100) |
| Adefovir | 2/13 (15.4) | (0) |
| Entecavir | 1/13 (7.7) | (0) |
| Tenofovir | (0) | 8/14 (57.1) |
| CD4 count (cells/μl) | ||
| Mean ± SD | NAb | 423 ± 304 |
| CD4 nadir (cells/μl) | ||
| Mean ± SD | NAb | 227 ± 142 |
| HIV-1 viral load Mean (copies/ml ± SD) | ||
| Mean ± SD | NAb | 2.29 × 103 ± 4.72 × 103 |
a
Precore could be assessed only for individuals with detectable HBV-DNA by PCR, which included only a subset of individuals in the study.
b
NA, not applicable.